SE512531C2 - Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur - Google Patents

Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Info

Publication number: SE512531C2
Authority: SE; Sweden
Prior art keywords: astaxanthin; disorders; mammalian muscle; prophylactic; xanthophyll
Prior art date: 1997-09-04

Application number

SE9703191A

Other languages

English (en)

Swedish (sv)

Other versions

SE9703191L (sv

SE9703191D0 (sv

Inventor

Aake Lignell

Original Assignee

Astacarotene Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-04

Filing date

1997-09-04

Publication date

2000-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE512531(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-09-04 Application filed by Astacarotene Ab filed Critical Astacarotene Ab

1997-09-04 Priority to SE9703191A priority Critical patent/SE512531C2/sv

1997-09-04 Publication of SE9703191D0 publication Critical patent/SE9703191D0/xx

1998-08-26 Priority to AT98943128T priority patent/ATE230985T1/de

1998-08-26 Priority to US09/485,704 priority patent/US6245818B1/en

1998-08-26 Priority to EP98943128A priority patent/EP1011653B1/de

1998-08-26 Priority to PCT/SE1998/001526 priority patent/WO1999011251A1/en

1998-08-26 Priority to ES98943128T priority patent/ES2191329T3/es

1998-08-26 Priority to AU90989/98A priority patent/AU727349B2/en

1998-08-26 Priority to DE69810784T priority patent/DE69810784T2/de

1998-08-26 Priority to CA002299366A priority patent/CA2299366C/en

1998-08-26 Priority to JP2000508354A priority patent/JP3660244B2/ja

1998-08-26 Priority to DK98943128T priority patent/DK1011653T3/da

1998-08-26 Priority to PL98338982A priority patent/PL338982A1/xx

1999-03-05 Publication of SE9703191L publication Critical patent/SE9703191L/

2000-03-02 Priority to NO20001087A priority patent/NO20001087L/no

2000-03-27 Publication of SE512531C2 publication Critical patent/SE512531C2/sv

Links

208000029578 Muscle disease Diseases 0.000 title claims abstract description 14
235000008210 xanthophylls Nutrition 0.000 title claims abstract description 12
239000003814 drug Substances 0.000 title claims abstract description 11
208000021642 Muscular disease Diseases 0.000 title claims abstract description 10
230000000069 prophylactic effect Effects 0.000 title claims abstract description 8
230000001225 therapeutic effect Effects 0.000 title claims abstract description 7
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title claims description 7
229960005375 lutein Drugs 0.000 title claims description 7
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title claims description 7
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title claims description 7
238000004519 manufacturing process Methods 0.000 title claims description 3
230000004220 muscle function Effects 0.000 title abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
208000035475 disorder Diseases 0.000 title description 2
JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 34
235000013793 astaxanthin Nutrition 0.000 claims abstract description 34
MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 34
229940022405 astaxanthin Drugs 0.000 claims abstract description 34
239000001168 astaxanthin Substances 0.000 claims abstract description 34
241000283086 Equidae Species 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 11
210000003205 muscle Anatomy 0.000 claims description 10
235000012054 meals Nutrition 0.000 claims description 9
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
150000004665 fatty acids Chemical class 0.000 claims description 4
241000168525 Haematococcus Species 0.000 claims description 3
208000008035 Back Pain Diseases 0.000 claims description 2
208000008930 Low Back Pain Diseases 0.000 claims description 2
230000003387 muscular Effects 0.000 claims 1
241000283073 Equus caballus Species 0.000 abstract description 3
238000000034 method Methods 0.000 abstract description 2
238000002360 preparation method Methods 0.000 abstract description 2
125000000264 xanthophyll group Chemical group 0.000 abstract 2
206010039020 Rhabdomyolysis Diseases 0.000 abstract 1
241000700159 Rattus Species 0.000 description 9
238000002474 experimental method Methods 0.000 description 7
230000000694 effects Effects 0.000 description 6
239000013589 supplement Substances 0.000 description 6
239000000902 placebo Substances 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
125000003999 astaxanthin group Chemical group 0.000 description 4
235000021466 carotenoid Nutrition 0.000 description 4
150000001747 carotenoids Chemical class 0.000 description 4
235000013312 flour Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
241000195493 Cryptophyta Species 0.000 description 3
206010033799 Paralysis Diseases 0.000 description 3
238000010586 diagram Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
150000003735 xanthophylls Chemical class 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
201000009623 Myopathy Diseases 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
208000018631 connective tissue disease Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
241000871264 Cardiospermum halicacabum Species 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
241000234314 Zingiber Species 0.000 description 1
235000006886 Zingiber officinale Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000008397 ginger Nutrition 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000001964 muscle biopsy Methods 0.000 description 1
239000012053 oil suspension Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000036314 physical performance Effects 0.000 description 1
238000003307 slaughter Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
235000013618 yogurt Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Fodder In General (AREA)

SE9703191A 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur SE512531C2 (sv)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
SE9703191A SE512531C2 (sv)	1997-09-04	1997-09-04	Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
DK98943128T DK1011653T3 (da)	1997-09-04	1998-08-26	Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
PL98338982A PL338982A1 (en)	1997-09-04	1998-08-26	Drug for improving duration of muscle action or for treating muscular disorders or diseases
ES98943128T ES2191329T3 (es)	1997-09-04	1998-08-26	Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
CA002299366A CA2299366C (en)	1997-09-04	1998-08-26	Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases
EP98943128A EP1011653B1 (de)	1997-09-04	1998-08-26	Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel-funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
PCT/SE1998/001526 WO1999011251A1 (en)	1997-09-04	1998-08-26	Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
AT98943128T ATE230985T1 (de)	1997-09-04	1998-08-26	Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
AU90989/98A AU727349B2 (en)	1997-09-04	1998-08-26	Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
DE69810784T DE69810784T2 (de)	1997-09-04	1998-08-26	Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel-funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
US09/485,704 US6245818B1 (en)	1997-09-04	1998-08-26	Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
JP2000508354A JP3660244B2 (ja)	1997-09-04	1998-08-26	筋肉機能の持続時間を改善し、または筋肉障害もしくは疾患を治療するための医薬品
NO20001087A NO20001087L (no)	1997-09-04	2000-03-02	Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9703191A SE512531C2 (sv)	1997-09-04	1997-09-04	Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Publications (3)

Publication Number	Publication Date
SE9703191D0 SE9703191D0 (sv)	1997-09-04
SE9703191L SE9703191L (sv)	1999-03-05
SE512531C2 true SE512531C2 (sv)	2000-03-27

Family

ID=20408142

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9703191A SE512531C2 (sv)	1997-09-04	1997-09-04	Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Country Status (13)

Country	Link
US (1)	US6245818B1 (de)
EP (1)	EP1011653B1 (de)
JP (1)	JP3660244B2 (de)
AT (1)	ATE230985T1 (de)
AU (1)	AU727349B2 (de)
CA (1)	CA2299366C (de)
DE (1)	DE69810784T2 (de)
DK (1)	DK1011653T3 (de)
ES (1)	ES2191329T3 (de)
NO (1)	NO20001087L (de)
PL (1)	PL338982A1 (de)
SE (1)	SE512531C2 (de)
WO (1)	WO1999011251A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7078040B2 (en)	2000-03-27	2006-07-18	Fuji Chemical Industry Co., Ltd.	Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0001071D0 (sv) *	2000-03-27	2000-03-27	Astacarotene Ab	Method of inhibiting the expression of inflammatory cytokines and chemokines
US6900324B2 (en)	2000-09-07	2005-05-31	Astrazeneca Ab	Process for preparing a substituted imidazopyridine compound
SE0003186D0 (sv) *	2000-09-07	2000-09-07	Astrazeneca Ab	New process
US7345091B2 (en)	2002-07-29	2008-03-18	Cardax Pharmaceuticals, Inc.	Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) *	2002-07-29	2005-07-07	Lockwood Samuel F.	Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) *	2002-07-29	2005-02-03	Lockwood Samuel Fournier	Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050004235A1 (en) *	2002-07-29	2005-01-06	Lockwood Samuel Fournier	Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en)	2002-07-29	2010-05-25	Cardax Pharmaceuticals, Inc.	Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7320997B2 (en)	2002-07-29	2008-01-22	Cardax Pharmaceuticals, Inc.	Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7763649B2 (en)	2002-07-29	2010-07-27	Cardax Pharmaceuticals, Inc.	Carotenoid analogs or derivatives for controlling connexin 43 expression
US7521584B2 (en) *	2002-07-29	2009-04-21	Cardax Pharmaceuticals, Inc.	Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) *	2002-07-29	2005-03-17	Lockwood Samuel Fournier	Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050059659A1 (en) *	2002-07-29	2005-03-17	Lockwood Samuel Fournier	Carotenoid analogs or derivatives for controlling C-reactive protein levels
CN101845009B (zh)	2002-07-29	2012-10-03	卡达克斯药物公司	用于抑制和改善疾病的类胡萝卜素结构类似物
US7375133B2 (en) *	2002-07-29	2008-05-20	Cardax Pharmaceuticals, Inc.	Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) *	2002-07-29	2005-06-30	Lockwood Samuel F.	Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050049248A1 (en) *	2002-07-29	2005-03-03	Lockwood Samuel Fournier	Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
AU2002329108A1 (en) *	2002-09-03	2004-03-29	Centro De Investigacion En Alimentacion Y Desarrollo A.C.	Method of preparing chitosan microcapsules of astaxanthin and product thus obtained
US8034372B2 (en) *	2003-03-05	2011-10-11	Nestec, Ltd.	Dietary supplement for athletic pets
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
US7727752B2 (en)	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
CA2445420A1 (en)	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
KR20060099524A (ko) *	2003-11-03	2006-09-19	아스트라제네카 아베	무증상 위식도 역류의 치료를 위한 이미다조[1,2-ａ]피리딘유도체
SE0303451D0 (sv) *	2003-12-18	2003-12-18	Astrazeneca Ab	New compounds
EP2653157B1 (de) *	2004-02-04	2016-08-03	Fuji Chemical Industry Co., Ltd.	Astaxanthin zur Verbesserung der Muskelatrophie
US20060058269A1 (en) *	2004-04-14	2006-03-16	Lockwood Samuel F	Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2564066A1 (en)	2004-04-14	2005-11-03	Hawaii Biotech, Inc.	Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2006039685A2 (en)	2004-10-01	2006-04-13	Hawaii Biotech, Inc.	Methods for synthesis of chiral intermediates of carotenoids, carotenoid analogs, and carotenoid derivatives
JP5196708B2 (ja) *	2005-02-04	2013-05-15	富士化学工業株式会社	アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
CA2610502A1 (en)	2005-03-29	2006-10-05	Cardax Pharmaceuticals, Inc.	Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) *	2008-05-30	2009-12-03	Yamaha Hatsudoki Kabushiki Kaisha	Method for Improving Cognitive Performance
US10867701B1 (en)	2010-06-28	2020-12-15	Heinrich Anhold	System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) *	2013-04-30	2016-05-25	株式会社ダイセル	抗疲労用組成物
CN112057420A (zh) *	2020-09-21	2020-12-11	中国科学院烟台海岸带研究所	一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2558372B1 (fr) *	1984-01-25	1987-08-07	Oreal	Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja)	1988-08-11	1997-06-11	サントリー株式会社	アスタキサンチン含有組成物
JPH0665033A (ja) *	1992-08-11	1994-03-08	Lion Corp	口腔用組成物
IL110139A0 (en) *	1993-06-28	1994-10-07	Howard Foundation	Pharmaceutically-active antioxidants
JPH10513444A (ja) *	1995-02-03	1998-12-22	ビーエーエスエフアクチェンゲゼルシャフト	皮膚疾患の治療のための医薬品の製造のためのカロチノイドの使用
JPH09124470A (ja) *	1995-10-26	1997-05-13	Suntory Ltd	抗ストレス組成物

1997
- 1997-09-04 SE SE9703191A patent/SE512531C2/sv not_active IP Right Cessation
1998
- 1998-08-26 AU AU90989/98A patent/AU727349B2/en not_active Ceased
- 1998-08-26 ES ES98943128T patent/ES2191329T3/es not_active Expired - Lifetime
- 1998-08-26 EP EP98943128A patent/EP1011653B1/de not_active Expired - Lifetime
- 1998-08-26 CA CA002299366A patent/CA2299366C/en not_active Expired - Lifetime
- 1998-08-26 WO PCT/SE1998/001526 patent/WO1999011251A1/en not_active Ceased
- 1998-08-26 AT AT98943128T patent/ATE230985T1/de not_active IP Right Cessation
- 1998-08-26 PL PL98338982A patent/PL338982A1/xx unknown
- 1998-08-26 DE DE69810784T patent/DE69810784T2/de not_active Expired - Lifetime
- 1998-08-26 JP JP2000508354A patent/JP3660244B2/ja not_active Expired - Lifetime
- 1998-08-26 US US09/485,704 patent/US6245818B1/en not_active Expired - Lifetime
- 1998-08-26 DK DK98943128T patent/DK1011653T3/da active
2000
- 2000-03-02 NO NO20001087A patent/NO20001087L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU727349B2 (en)	2000-12-14
NO20001087D0 (no)	2000-03-02
EP1011653B1 (de)	2003-01-15
DE69810784D1 (de)	2003-02-20
DE69810784T2 (de)	2003-11-13
WO1999011251A1 (en)	1999-03-11
ATE230985T1 (de)	2003-02-15
NO20001087L (no)	2000-03-02
CA2299366A1 (en)	1999-03-11
AU9098998A (en)	1999-03-22
US6245818B1 (en)	2001-06-12
ES2191329T3 (es)	2003-09-01
EP1011653A1 (de)	2000-06-28
PL338982A1 (en)	2000-12-04
DK1011653T3 (da)	2003-05-26
SE9703191L (sv)	1999-03-05
SE9703191D0 (sv)	1997-09-04
JP3660244B2 (ja)	2005-06-15
CA2299366C (en)	2008-04-22
JP2001514215A (ja)	2001-09-11

Legal Events

Date	Code	Title	Description
2017-10-31	NUG	Patent has lapsed

Publication	Publication Date	Title
SE512531C2 (sv)	2000-03-27	Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
DE69821123T2 (de)	2004-10-14	Diätzusammensetzung zur steigerung des metabolismus und zur linderung von oxydativem stress
JP2925326B2 (ja)	1999-07-28	ヒトの窒素保持の促進方法
EP2859896B1 (de)	2018-01-31	Pharmazeutische Zusammensetzungen zur Behandlung von Muskelkrankheiten
US10821153B2 (en)	2020-11-03	Composition for improving muscular function or for enhancing exercise performance comprising vigna angularis var. angularis
US20210128664A1 (en)	2021-05-06	Agent for Activating Astrocyte Glucose Metabolism
US20210369663A1 (en)	2021-12-02	Compositions and methods using a combination of curcumin and an omega-3 fatty acid for cellular energy
Reddy et al.	1966	Serum vitamin A in kwashiorkor
JP2011207815A (ja)	2011-10-20	抗酸化ストレス剤
EP3135281B1 (de)	2020-10-28	Zusammensetzung zur prävention oder verbesserung von peripherer neuropathie
US20170182106A1 (en)	2017-06-29	Composition including kirenol or siegesbeckia herba extract for muscle function improvement or exercise ability enhancement
KR20100016096A (ko)	2010-02-12	제니스테인의 신규 용도
US8673287B2 (en)	2014-03-18	Anti-obesity composition containing acacia bark derivative
SE524337C2 (sv)	2004-07-27	Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk behandling av matsmältningsbesvär
US20190183811A1 (en)	2019-06-20	Composition containing squalene for improving muscle function and preventing muscle damage
US20220088106A1 (en)	2022-03-24	Composition comprising cudrania tricuspidate as effective component for alleviating, treating, or preventing muscular diseases, or improving muscule functions
KR20190003570A (ko)	2019-01-09	안전한·안정된 플라스마로겐과 그 제제 및 인지증의 미병 상태의 판정 방법
US20080312149A1 (en)	2008-12-18	Health Food and Pharmaceutical Composition for Amelioration of Disease Induced by Metabolic Disorder in Cartilage
KR102467123B1 (ko)	2022-11-14	갯질경 추출물을 포함하는 지구력 증진용 조성물
Ismael et al.	2021	Effects of Cisplatin on Glycemic Control and Lipid Profile in Male Albino Rats Role of Propolis
US20190350224A1 (en)	2019-11-21	Method for improving muscle force or physical function
KR20130112212A (ko)	2013-10-14	셀라스트롤을 포함하는 근피로 저항 또는 근질량 증가용 조성물
CN113490422A (zh)	2021-10-08	用于抑制/减少体重增加的组合物
WO2017130638A1 (ja)	2017-08-03	アストロサイトのグルコース代謝活性化剤
WO2013058194A1 (ja)	2013-04-25	Ｓｒｆシグナル活性化剤